177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Ian F. Tannock, Ronald de Wit, William R. Berry et al. · New England Journal of Medicine · 2004 · 5.7K citations

Medicine, Oncology, Urology +12

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Daniel P. Petrylak, Catherine M. Tangen, Maha Hussain et al. · New England Journal of Medicine · 2004 · 3.7K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +13

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

Stephanie Green, Geoffrey R. Weiss · Investigational New Drugs · 1992 · 616 citations

Medicine, Oncology, Medical Oncology +14

Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer

Martina Benešová, Martin Schäfer, Ulrike Bauder‐Wüst et al. · Journal of Nuclear Medicine · 2015 · 594 citations

Medicine, Medicinal Chemistry, Pharmacology +17

¹⁷⁷Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

Richard P. Baum, Harshad Kulkarni, Christiane Schuchardt et al. · Journal of Nuclear Medicine · 2016 · 526 citations · Full text

Medicine, Nuclear Medicine, Oncology +17